Taiho gets first anti-cancer recommended for approval outside of Asia
This article was originally published in Scrip
Executive Summary
Taiho Pharmaceutical's oral chemotherapy drug Teysuno (S-1) has been recommended for European approval by the CHMP for the treatment of advanced gastric cancer (in combination with cisplatin), representing the first regulatory milestone for Taiho outside of Asia.